We are live on ! Find out more
ABVC icon

ABVC BioPharma
ABVC

9 hedge funds and large institutions have $79.8K invested in ABVC BioPharma in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

0.17% more ownership

Funds ownership: 1.78% → 1.94% (+0.17%)

0% more funds holding

Funds holding: 9 → 9 (0)

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

74% less capital invested

Capital invested by funds: $304K → $79.8K (-$224K)

Holders
9
Holders Change
–
Holders Change %
0%
% of All Funds
0.14%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
3
Reduced
2
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
+$49K
2
Citadel Advisors
Citadel Advisors
Florida
+$37.7K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$13.4K
4
TRCT
Tower Research Capital (TRC)
New York
+$3.86K
5
Wells Fargo
Wells Fargo
California
+$12

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$49.4K
2
Two Sigma Investments
Two Sigma Investments
New York
-$11.5K
3
Northern Trust
Northern Trust
Illinois
-$9.57K
4
BlackRock
BlackRock
New York
-$3.02K
5
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$2

ABVC Hedge Fund Activity: Q3 2023 in Review

9 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in ABVC BioPharma (ABVC) for Q3 2023, worth a combined $79.8K — down 74% from $304K a quarter earlier.

Fund positioning in ABVC was balanced in Q3 2023: 3 funds opened new positions, 3 closed out, 3 added to existing stakes and 2 trimmed.

The largest buyer was Virtu Financial, opening a new position worth an estimated $49K. The largest seller was Vanguard Group, cutting an estimated $49.4K.

  • 9 institutional investors held ABVC BioPharma (ABVC) as of Q3 2023, unchanged from Q2 2023.
  • Funds reported $79.8K of ABVC BioPharma stock for Q3 2023, down 74% quarter-over-quarter.
  • 3 funds opened new ABVC BioPharma positions in Q3 2023 and 3 closed out, a net change of 0 holders.
  • The largest ABVC BioPharma buyer in Q3 2023 was Virtu Financial, an estimated $49K added.
  • The largest ABVC BioPharma seller in Q3 2023 was Vanguard Group, an estimated $49.4K sold.

Based on aggregated 13F filings for Q3 2023.